Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

The FDA accepts Merck's (MRK) resubmission of a New Drug Application for its sugammadex sodium...

  • Monday, January 7, 8:40 AM ET
    The FDA accepts Merck's (MRK) resubmission of a New Drug Application for its sugammadex sodium injection, which is used as a muscle relaxant during surgery. The FDA rejected the original NDA for sugammadex in 2008 and asked for additional information about allergic reactions and bleeding. (PR)
Track new comments on this story

This news story has 1 comment:

  •  
    Actually sugammadex is not a muscle relaxant. It is the first selective relaxant binding agent indicated to reverse the neuromuscular blockade induced during general anaesthesia. It blocks the action of rocuronium, which is a muscle relaxant.
    7 Jan, 05:18 PM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »